lilly glp 1 agonist Diabetes Patients Also Struggle to Access GLP-1 Agonists Medscape | Orforglipron, Eli Lilly's

doi:10.1210/endo-101-2-635 138

Why It Matters Additional randomized, controlled trials that follow people over time are needed to confirm these findings, but these results are promising, since people with diabetes are at increased risk for developing epilepsy later in life, said study author Edy Kornelius, MD, PhD, of Chung Shan Medical University in Taichung, Taiwan

Link: FDA Warning LetterRead the warning letters for a complete description of violations

Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes

Ziyad Al-Aly

doi: 10.1016/j.bbrc.2018.10.197 66 WuXLiSXuePLiY